Tasuku Honjo, a Nobel laureate in Physiology or Medicine and distinguished professor at Kyoto University, told The Yomiuri Shimbun Monday that the nation's first cancer immunotherapy research center would be established in Kyoto University on April 1.
Honjo, who paved the way for cancer immunotherapy, will serve as head of the center.
The university will establish the center using existing facilities for the time being. A research building will be constructed in fiscal 2022, with six research departments eventually being set up to study ways to increase effectiveness of the cancer immunotherapy drug Opdivo, which was developed on the basis of Honjo's research, as well as predict its effectiveness in advance.
Read more from The Japan News at https://japannews.yomiuri.co.jp/
